Designer Babies: Human cloning is a long way off, but bioengineered kids are already here.
By Shannon Brownlee,
The Washington Monthly
| 02. 28. 2002
In the mid-1990s, embryologist Jacques Cohen pioneered a promising
new technique for helping infertile women have children. His
technique, known as cytoplasmic transfer, was intended to "rescue"
the eggs of infertile women who had undergone repeated, unsuccessful
attempts at in vitro fertilization, or IVF. It involved injecting
the cytoplasm found inside the eggs of a fertile donor, into
the patient's eggs.
When the first baby conceived through cytoplasmic transfer was
born in 1997, the press instantly hailed Cohen's technique as
yet another technological miracle. But four years later, the
real story has proven somewhat more complicated. Last year,
Cohen and his colleagues at the Institute for Reproductive Medicine
and Science of St. Barnabas, a New Jersey fertility clinic,
set off alarm bells among bioethicists with the publication
of a paper detailing the genetic condition of two the 17 cytoplasmic-transfer
babies born through the clinic to date. The embryologists reported
that they had endowed the children with extra bits of a special
type of genetic material, known as mitochondrial DNA, or mtDNA,
which came with the cytoplasm transferred from the donor...
Related Articles
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...